Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398710 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1MAPTLMNARECQL | |
| SCHEMBL3789171 | 0.85 | NTRK1 (0.52) | SMN1; SMN2ALDH1A1MAPTLMNARECQL | |
| SCHEMBL3795995 | 0.83 | NTRK1 (0.50) | SMN1; SMN2ALDH1A1MAPTLMNARECQL | |
| SCHEMBL3397806 | 0.82 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1MAPTLMNARECQL | |
| SCHEMBL3396618 | 0.81 | L3MBTL1 (0.69) | SMN1; SMN2ALDH1A1MAPTLMNANTRK1 | |
| SCHEMBL3395973 | 0.80 | ALDH1A1 (0.74) | SMN1; SMN2ALDH1A1MAPTLMNARECQL | |
| SCHEMBL3397102 | 0.80 | L3MBTL1 (0.67) | SMN1; SMN2ALDH1A1MAPTLMNANTRK1 | |
| SCHEMBL13183040 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTKMT2ANPC1RAB9A | |
| SCHEMBL3395315 | 0.74 | ALDH1A1 (0.76) | SMN1; SMN2ALDH1A1MAPTLMNARECQL | |
| SCHEMBL3789990 | 0.74 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1MAPTLMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222381-A1 | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors | VANKAYALAPATI HARIPRASAD | 2010-09-02 | — | — | US | claimed |
| US-20100222381-A1 | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors | VANKAYALAPATI HARIPRASAD | 2010-09-02 | — | — | US | disclosed |
| US-20100222381-A1 | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors | VANKAYALAPATI HARIPRASAD | 2010-09-02 | — | — | US | disclosed |
| US-20100222381-A1 | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors | VANKAYALAPATI HARIPRASAD | 2010-09-02 | — | — | US | disclosed |
| WO-2010098866-A1 | CYCLOPENTATHIOPHENE/CYCLOHEXATHIOPHENE DNA METHYLTRANSFERASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222381-A1 | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors | DNMT3B, DNMT1, DNMT3L | SMN1; SMN2 2791/4885ALDH1A1 982/4885MAPT 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.